Updates are available Correction dated 2021-10-08
Click to view Correction: https://doi.org/10.1038/s43018-021-00283-9
-
Authors
Ferraro, Gino B. http://orcid.org/0000-0002-1587-4259
Ali, Ahmed
Luengo, Alba http://orcid.org/0000-0002-4236-0229
Kodack, David P.
Deik, Amy
Abbott, Keene L. http://orcid.org/0000-0002-6166-704X
Bezwada, Divya http://orcid.org/0000-0002-5434-2976
Blanc, Landry http://orcid.org/0000-0001-5622-356X
Prideaux, Brendan
Jin, Xin http://orcid.org/0000-0003-4167-1743
Posada, Jessica M.
Chen, Jiang
Chin, Christopher R.
Amoozgar, Zohreh
Ferreira, Raphael http://orcid.org/0000-0001-9881-6232
Chen, Ivy X.
Naxerova, Kamila
Ng, Christopher
Westermark, Anna M.
Duquette, Mark
Roberge, Sylvie
Lindeman, Neal I.
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Nielsen, Jens http://orcid.org/0000-0002-9955-6003
Housman, David E.
Duda, Dan G. http://orcid.org/0000-0001-7065-8797
Brachtel, Elena
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Asara, John M.
Davidson, Shawn M.
Fukumura, Dai http://orcid.org/0000-0002-9505-4444
Dartois, Véronique A.
Clish, Clary B. http://orcid.org/0000-0001-8259-9245
Jain, Rakesh K. http://orcid.org/0000-0001-7571-3548
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA197742, U01CA224173, R35CA242379, R01CA201276, P30CA14051)
Howard Hughes Medical Institute (55108580)
- License Information
-
More Information
Article History
Received: 21 October 2020
Accepted: 8 February 2021
First Online: 1 April 2021
Change Date: 8 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-021-00283-9
Competing interests
: A.L. is a current employee of a Flagship Pioneering biotechnology start-up company. I.X.C. is a current employee of Stimit Corporation. D.G.D. received consultant fees from Bayer, Simcere and BMS and research grants from Bayer, Exelixis and BMS. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals. R.K.J received honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer, SPARC, SynDevRx; owns equity in Accurius, Enlight, Ophthotech, SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund. Neither any reagent nor any funding from these organizations was used in this study. M.G.V.H. is a scientific advisory board member for Agios Pharmaceuticals, Aeglea Biotherapeutics, Auron Therapeutics, Faeth Therapeutics and iTeos Therapeutics.
